Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization

Oxana P Trifonova 1, Dmitri L Maslov 1, Elena E Balashova 1, Guzel R Urazgildeeva 2, Denis A Abaimov 2, Ekaterina Yu Fedotova 2, Vsevolod V Poleschuk 2, Sergey N Illarioshkin 2, Petr G Lokhov 1

Affiliations

PMID: 32466249
DOI: 10.3390/diagnostics10050339

Free article

Abstract

Parkinson's disease is the second most frequent neurodegenerative disease, representing a significant medical and socio-economic problem. Modern medicine still has no answer to the question of why Parkinson's disease develops and whether it is possible to develop an effective system of prevention. Therefore, active work is currently underway to find ways to assess the risks of the disease, as well as a means to extend the life of patients and improve its quality. Modern studies aim to create a method of assessing the risk of occurrence of Parkinson's disease (PD), to search for the specific ways of correction of biochemical disorders occurring in the prodromal stage of Parkinson's disease, and to personalize approaches to antiparkinsonian pharmacotherapy. In this review, we summarized all available clinically approved tests and techniques for PD diagnostics. Then, we reviewed major improvements and recent advancements in genomics, transcriptomics, and proteomics studies and application of metabolomics in PD research, and discussed the major metabolomics findings for diagnostics and therapy of the disease.

Keywords: Parkinson's disease; biomarker; clinical test; diagnostics; metabolomics; pharmacotherapy personalization.